Corydalis

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: pain inflammation stress

Research Overview

Across the studies, Corydalis research is most concentrated in (1) analgesia and pain-related applications (often framed as alternatives to opioids or as components of multi-herb formulas), (2) cardiovascular/thrombotic indications linked to “blood stasis” concepts, and (3) liver-related effects, spanning both hepatoprotection (e.g., nonalcoholic fatty liver disease) and hepatotoxicity surveillance. A recurring focus is on alkaloid-rich extracts and specific alkaloids—particularly tetrahydropalmatine (THP/TET) and related compounds—investigated in preclinical models for mechanistic pathways such as PI3K–Akt and AMPK–SREBP1, as well as oxidative stress and inflammatory signaling.

The strongest evidence in these studies supports mechanistic and efficacy signals in animal and cellular models rather than definitive clinical benefit. For thrombosis, Corydalis decumbens extracts/alkaloids and isolated compounds (e.g., tetrahydropalmatine, protopine) reduced thrombus formation and platelet aggregation in vivo, with pathway-level associations (PI3K–Akt inhibition) and reductions in injury/oxidative stress markers. For metabolic liver disease, Corydalis saxicola total alkaloids improved multiple NAFLD hallmarks in diet-induced mice and showed convergent mechanistic evidence (RNA-seq/qPCR and tracer studies) consistent with reduced de novo lipogenesis via AMPK activation and impaired SREBP1 maturation. In parallel, safety-focused evidence indicates Corydalis yanhusuo is repeatedly implicated among leading herbs associated with herb-induced liver injury in case cohorts, supporting a credible signal that hepatotoxicity risk exists in real-world use even as other Corydalis preparations are studied for hepatoprotection.

Key gaps include limited high-quality human clinical trials establishing efficacy, dose–response, and comparative effectiveness for specific Corydalis species, standardized extracts, or purified alkaloids across indications (pain, thrombosis, NAFLD, wound/flap survival). More research is also needed to reconcile benefit–risk profiles across species and preparations, including rigorous pharmacovigilance, identification of hepatotoxic constituents and patient risk factors, and interaction studies (e.g., with opioids, anticoagulants/antiplatelets, and other hepatically metabolized drugs). Finally, mechanistic findings (PI3K/AKT/mTOR, AMPK–SREBP1, angiogenesis/autophagy pathways) require stronger causal validation and translational work to determine whether these pathways predict clinically meaningful outcomes and safety in humans.

1. What conditions has Corydalis been studied for?

  • Pain/analgesia: Corydalis yanhusuo monomers (tetrahydropalmatine, corydaline, protopine, dehydrocorydaline) were tested in a formalin-induced pain model; a review also discusses Chinese herbs (including Corydalis) for pain management.

  • Thrombosis/platelet aggregation: Corydalis decumbens extract/alkaloids (including tetrahydropalmatine and protopine) studied in a carrageenan-induced mouse thrombus model and rabbit platelet aggregation assay.

  • Nonalcoholic fatty liver disease (NAFLD): Corydalis saxicola Bunting total alkaloids (CSBTA) studied in high-fat/high-cholesterol diet (HFHCD) mice and hepatocyte models.

  • Myocardial ischemia-reperfusion injury (MIRI): Dehydrocorydaline (DHC) studied in a mouse MIRI model and H9c2 hypoxia/reoxygenation cells.

  • Skin flap survival/ischemic necrosis after transplantation: Tetrahydropalmatine (THP) studied in a modified McFarlane flap model.

  • Opioid-related immune effects (as part of a multi-herb formula): Corydalis yanhusuo included in “Compound 511,” studied for morphine-induced immunosuppression and susceptibility to MRSA infection in mice.

  • Herb-induced liver injury (HILI) risk: Corydalis yanhusuo is listed among the main herbs implicated in HILI cases in a systematic review of DILI/HILI cohorts.

  • Rheumatoid arthritis (RA): Corydalis decumbens is described as used for RA for decades; the study fragment indicates anti-inflammatory targeting but is incomplete.

  • Osteoporosis (context only): One excerpt discusses postmenopausal osteoporosis generally, but the provided Corydalis studies do not show direct osteoporosis outcomes.

2. Does it work in treating those conditions? Summarize the evidence.

  • Pain: In vivo formalin pain testing showed that four Corydalis yanhusuo monomers (THP, corydaline, protopine, DHC) all had analgesic activity. Mechanistically, they inhibited Nav1.7 peak currents and altered activation/inactivation kinetics, suggesting a plausible analgesic target (VGSC/Nav1.7). The study concluded THP had the “best analgesic effect” and “lowest cardiac risk” among the tested monomers.

    Limitations: Evidence here is preclinical (animal model + electrophysiology), not human clinical trials.

  • Thrombosis/platelet aggregation: Corydalis decumbens total extract, total alkaloids, and tetrahydropalmatine reduced “black tail thrombus and congestion” in a mouse thrombosis model and decreased rabbit platelet aggregation. The study also reports reduced ROS/LDH and involvement of PI3K-Akt pathway inhibition as a proposed mechanism.

    Limitations: Animal and ex vivo data; no clinical outcomes reported.

  • NAFLD: CSBTA improved multiple NAFLD hallmarks in HFHCD-fed mice (reduced lipid accumulation, liver injury, inflammation, fibrosis). RNA-seq/qPCR showed suppression of lipogenesis genes (Srebf1, Acc1, Fasn). Stable isotope tracer testing suggested reduced lipid accumulation by interrupting fatty acid biosynthesis. Mechanism proposed: AMPK activation impeding SREBP1 maturation (AMPK–SREBP1 axis).

    Limitations: Mouse and cell models; translation to humans is uncertain, and dosing/standardization of “total alkaloids” mixtures can vary.

  • MIRI/cardioprotection: DHC (5 mg/kg i.p.) improved cardiac function measures (left ventricular ejection fraction and fractional shortening), reduced infarct size, and lowered injury biomarkers (cTnI, LDH) in a mouse MIRI model. In vitro, DHC reduced apoptosis/oxidative stress in hypoxia/reoxygenation H9c2 cells; network pharmacology + docking/MST supported interactions with targets (e.g., CCND1, CDK2, MDM2) and involvement of FoxO signaling and apoptosis-related proteins.

    Limitations: Preclinical; network pharmacology/docking is hypothesis-generating and not definitive proof of in vivo target engagement in humans.

  • Skin flap survival: THP increased flap survival rate, promoted angiogenesis and perfusion, and reduced inflammation, oxidative stress, apoptosis, and autophagy markers. The mechanism was linked to PI3K/AKT/mTOR signaling; rapamycin (mTOR inhibitor) partially reversed THP’s effects, supporting pathway involvement.

    Limitations: Surgical animal model; relevance to human reconstructive surgery requires clinical trials.

  • Opioid-induced immunosuppression (formula evidence): In morphine-immunosuppressed mice, Compound 511 (which includes Corydalis yanhusuo among eight herbs) corrected Th1/Th2 and Treg/Th17 imbalance, altered transcription factors (reduced FOXP3 and GATA3; increased STAT3 and T-bet), and reduced MRSA-related lung inflammation. Mechanism implicated PI3K/AKT/mTOR signaling.

    Limitations: Multi-herb formula—cannot attribute effects specifically to Corydalis; animal data only.

  • RA: The provided RA abstract is incomplete; it supports traditional use but does not provide results here, so efficacy cannot be concluded from the supplied text.

3. What health benefits does it have?

  • Analgesic effects: Multiple Corydalis yanhusuo alkaloids reduced pain behavior in a formalin model; Nav1.7 inhibition is a plausible mechanism for analgesia.

  • Antithrombotic/anti-platelet effects: Corydalis decumbens extracts/alkaloids reduced thrombosis signs in mice and decreased platelet aggregation in rabbits; PI3K-Akt pathway inhibition and reduced oxidative injury markers were reported.

  • Potential liver-metabolic benefits (NAFLD): CSBTA reduced hepatic fat accumulation and improved inflammatory/fibrotic features in diet-induced NAFLD mice, likely via AMPK activation and suppression of SREBP1-driven de novo lipogenesis.

  • Cardioprotection in ischemia-reperfusion models: DHC reduced infarct size and improved cardiac function in MIRI mice and reduced apoptosis/oxidative stress in vitro, with FoxO signaling implicated.

  • Microcirculation/tissue survival support in ischemic injury models: THP improved skin flap survival, angiogenesis, and perfusion while reducing inflammation/oxidative stress and modulating PI3K/AKT/mTOR-related autophagy and apoptosis markers.

  • Immune modulation (indirect evidence): In a multi-herb formula context, inclusion of Corydalis yanhusuo was part of an intervention that improved morphine-associated immune imbalance and reduced MRSA lung inflammation in mice (attribution to Corydalis alone is not established).

4. Does it have any downsides or side effects?

  • Potential hepatotoxicity (herb-induced liver injury): A systematic review of DILI/HILI cohorts found 25% of overall liver injury cases were implicated in herbs, and listed Corydalis yanhusuo among the main herbs causing HILI. HILI cases were more common in females and were predominantly hepatocellular injury patterns in that dataset.

    Important nuance: This does not quantify the absolute risk for a typical user; it indicates Corydalis yanhusuo appears in reported HILI case cohorts and should be considered a potential risk, especially with high doses, prolonged use, product adulteration/misidentification, or pre-existing liver disease.

  • Potential cardiac electrophysiology risk (compound-specific): In the monomer comparison study, protopine increased CK-MB and affected Nav1.5 currents (cardiac sodium channel), suggesting a potential cardiac risk signal for that specific alkaloid. The authors concluded THP had the lowest cardiac risk among the tested monomers.

  • Mechanism-based interaction concerns (theoretical from studies): Several studies implicate PI3K/AKT/mTOR signaling modulation (e.g., thrombosis, flap survival, immune effects). While not direct evidence of adverse events, pathway modulation raises the possibility of drug interactions or off-target effects depending on clinical context (e.g., concurrent immunomodulators or anticoagulants). The studies do not provide human interaction data.

  • Evidence limitations: Much of the efficacy and mechanistic work is preclinical; safety in humans depends on dose, preparation (single alkaloid vs total alkaloids vs whole herb), and individual susceptibility. The studies reviewed here do not include controlled human safety trials.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The studies reviewed here do not report pharmacogenomic analyses (e.g., outcomes stratified by genotype, or specific gene variants affecting response/toxicity) for Corydalis species or their alkaloids.

  • No direct evidence in the supplied studies linking Corydalis response or adverse effects to specific human genetic variants (e.g., CYP metabolism variants, ion-channel variants, or pathway polymorphisms).

  • Mechanistic hints are not pharmacogenomics: Studies implicate targets/pathways such as Nav1.7/Nav1.5, PI3K/AKT/mTOR, AMPK–SREBP1, and FoxO signaling, but they do not test whether genetic variation in these pathways changes efficacy or risk.

References

  1. Advances in phytochemical and modern pharmacological research of
    Bing Tian, Ming Tian, Shu-Ming Huang (2020) - Pharmaceutical biology
  2. Effects of Herbal Medicines on Pain Management.
    Yun Luo, Chong-Zhi Wang, Richard Sawadogo, Ting Tan, Chun-Su Yuan (2020) - The American journal of Chinese medicine
  3. Thrombosis inhibited by Corydalis decumbens through regulating PI3K-Akt pathway.
    Song Chen, Cai-Bo Tian, Li-Yu Bai, Xing-Chao He, Qing-Yu Lu, Yun-Li Zhao, Xiao-Dong Luo (2024) - Journal of ethnopharmacology
  4. Systematic review of published data on herb induced liver injury.
    Jung-Hwan Byeon, Ji-Hye Kil, Yo-Chan Ahn, Chang-Gue Son (2019) - Journal of ethnopharmacology
  5. Corydalis saxicola Bunting total alkaloids improve NAFLD by suppressing de novo lipogenesis through the AMPK-SREBP1 axis.
    Yating Guo, Qiushuang Sun, Shijiao Wang, Mengdi Zhang, Yuanyuan Lei, Jiejie Wu, Xinhong Wang, Wenjun Hu, Haitao Meng, Zhiyu Li, Luzhou Xu, Fang Huang, Zhixia Qiu (2024) - Journal of ethnopharmacology
  6. Compound 511 ameliorates MRSA-induced lung injury by attenuating morphine-induced immunosuppression in mice via PI3K/AKT/mTOR pathway.
    Zhonghao Li, Qinmei Sun, Qingyang Liu, Xinru Mu, Hui Wang, Han Zhang, Fenfen Qin, Qisheng Wang, Dengyun Nie, Anlong Liu, Qian Li, Jianjian Ji, Yongwei Jiang, Shengfeng Lu, Qian Wang, Zhigang Lu (2023) - Phytomedicine : international journal of phytotherapy and phytopharmacology
  7. Tetrahydropalmatine promotes random skin flap survival in rats via the PI3K/AKT signaling pathway.
    Jialong Yang, Jiapeng Deng, Kaitao Wang, An Wang, Guodong Chen, Qingyu Chen, Minle Ye, Xinyu Wu, Xinye Wang, Dingsheng Lin (2024) - Journal of ethnopharmacology
  8. Dehydrocorydaline attenuates myocardial ischemia-reperfusion injury via the FoXO signalling pathway: A multimodal study based on network pharmacology, molecular docking, and experimental study.
    Hongzheng Li, Wenwen Yang, Zucheng Shang, Yingdong Lu, Aling Shen, Daxin Chen, Guosheng Lin, Mengfan Li, Renfeng Li, Meizhu Wu, Zhi Guo, Hua Qu, Changgeng Fu, Zikai Yu, Keji Chen (2025) - Journal of ethnopharmacology
  9. Analgesic effect of the main components of Corydalis yanhusuo (yanhusuo in Chinese) is caused by inhibition of voltage gated sodium channels.
    Yijia Xu, Jianfang Sun, Wenwen Li, Suli Zhang, Liying Yang, Ying Teng, Kaikai Lv, Yanfeng Liu, Yang Su, Jinghai Zhang, Mingyi Zhao (2021) - Journal of ethnopharmacology
  10. Corydalis decumbens and tetrahydropalmatrubin inhibit macrophages inflammation to relieve rheumatoid arthritis by targeting Fosl2.
    Peng Gao, Shuo Yuan, Yanhang Wang, Yuqi Wang, Xiaoshuang Li, Tingting Liu, Yongzhe Zheng, Jing Wang, Dan Liu, Luzheng Xu, Yong Jiang, Kewu Zeng, Pengfei Tu (2025) - Journal of ethnopharmacology
  11. Endothelial-Dependent and Independent Vascular Relaxation Effect of Tetrahydropalmatine on Rat Aorta.
    Zhong-Yan Zhou, Wai-Rong Zhao, Wen-Ting Shi, Ying Xiao, Zi-Lin Ma, Jin-Gui Xue, Lun-Qing Zhang, Qing Ye, Xin-Lin Chen, Jing-Yi Tang (2019) - Frontiers in pharmacology
  12. Systematic review of the alkaloid constituents in several important medicinal plants of the Genus Corydalis.
    Ai-Ping Deng, Yue Zhang, Li Zhou, Chuan-Zhi Kang, Chao-Gen Lv, Li-Ping Kang, Tie-Gui Nan, Zhi-Lai Zhan, Lan-Ping Guo, Lu-Qi Huang (2021) - Phytochemistry
  13. Identification and Quantification, Metabolism and Pharmacokinetics, Pharmacological Activities, and Botanical Preparations of Protopine: A Review.
    Wangli Huang, Lingbo Kong, Yang Cao, Liang Yan (2021) - Molecules (Basel, Switzerland)
  14. Exploring the role of Chinese herbal medicine in the long-term management of postoperative ovarian endometriotic cysts: a systematic review and meta-analysis.
    Danni Ding, Shaoxuan Liu, Fangyuan Liu, Songli Hao, Chunlan Zhang, Ying Shen, Wei Wei, Qiaochu Chen, Fengjuan Han (2024) - Frontiers in pharmacology
  15. Fingerprint-efficacy study of the quaternary alkaloids in Corydalis yanhusuo.
    Qiuyue Li, Huanyu Guan, Xiaoming Wang, Yang He, Hong Sun, Wenting Tan, Xiaomei Luo, Meifeng Su, Yue Shi (2017) - Journal of ethnopharmacology
  16. Investigation of the Therapeutic Effect of Total Alkaloids of
    Qianyi Wang, Zhuo Luo, Danfeng Li, Jinghua Qin, Ziping Pan, Bingjian Guo, Lijun Deng, Yunyuan Nong, Zheng Huang, Ying He, Hongwei Guo, Dan Zhu, Yonghong Liang, Zhiheng Su (2022) - Metabolites
  17. Corydalis tomentella Franch. Exerts anti-inflammatory and analgesic effects by regulating the calcium signaling pathway.
    Shuyi Jin, Yveting Li, Chuan Luo, Xinyi Cheng, Wei Tao, Hongting Li, Wanli Wang, Minjian Qin, Guoyong Xie, Feng Han (2024) - Journal of ethnopharmacology
  18. Corynoline Alleviates Osteoarthritis Development via the Nrf2/NF-
    Sunlong Li, Yifeng Shi, Shuhao Zhang, Haobin Li, Ziyang Ye, Jiangqian Kong, Weijun Hong, Yiting Tu, Jiaping Ren, Zaher Meftah, Chenglong Xie, Xiangyang Wang, Xiaolei Zhang (2022) - Oxidative medicine and cellular longevity
  19. Network pharmacology analysis of the active ingredients of Corydalis hendersonii Hemsl. and their effects on eliminating neuroinflammation and improving motor functions in MPTP-intoxicated mice.
    Jun Wang, Qiu-Tong Liu, Dan-Yang Shen, Jin-Peng Bai, Yang Hu, Qin Huang, Hui-Jing Yu, Ning-Ning He, Xiao-Yan Qin, Rongfeng Lan (2024) - Journal of ethnopharmacology


Related

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.

Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!